Trial Information

Angiogenesis Pathway Gene Polymorphisms Associated With Clinical Outcome in Patients Enrolled in ECOG 4599

OBJECTIVES:

Primary

- To determine whether germline polymorphisms (DNA) of genes involved in DNA repair
(e.g., XPD, ERCC-1, and others) and angiogenesis (e.g., vascular endothelial growth
factor [VEGF], interleukin-8, CXCR2, adrenomedullin, leptin, and others) are associated
with toxicity and clinical outcome in patients with non-small cell lung cancer enrolled
on protocol ECOG-4599.

OUTLINE: Blood samples previously obtained from patients on protocol ECOG-4599 are analyzed
for the association of germline variations of genes involved in DNA repair (XPD and ERCC1),
angiogenesis (VEGF and IL-8), and clinical outcome (overall survival, response,
progression-free survival, and toxicity).

Tumor cells are collected from paraffin-embedded tissue using laser-capture microdissection
and normal tissue is collected from the specimen. Polymorphisms in ERCC-1, XRCC-1, XRCC-3,
GST-P1, TGF-β, and IL-8CXCR are assessed using Taqman assays.